Patents by Inventor Michael R. Elashoff
Michael R. Elashoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150315652Abstract: Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.Type: ApplicationFiled: July 17, 2015Publication date: November 5, 2015Inventors: Steven Rosenberg, Michael R. Elashoff, Philip Beineke, James A. Wingrove, Whittemore G. Tingley, Susan E. Daniels
-
Patent number: 9122777Abstract: Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.Type: GrantFiled: June 15, 2010Date of Patent: September 1, 2015Assignee: CardioDx, Inc.Inventors: Steven Rosenberg, Michael R. Elashoff, Philip Beineke, James A. Wingrove, Whittemore G. Tingley, Susan E. Daniels
-
Patent number: 8914240Abstract: Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.Type: GrantFiled: January 16, 2014Date of Patent: December 16, 2014Assignee: Cardiodx, Inc.Inventors: Steven Rosenberg, Michael R. Elashoff, Philip Beineke, James A. Wingrove, Whittemore G. Tingley, Susan E. Daniels
-
Patent number: 8825587Abstract: Biomarkers useful for diagnosing and assessing physiological age are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers include a group of biomarkers whose expression levels are highly correlated to each other. In a preferred embodiment, expression levels of CD248; CD248 and SLC 1A7; CD248 and one, two, three or four of the group consisting of CCR7, B3GAT1, VSIG4 and LRRN3; or CD248, SLC1A7 and one, two, three or four of the group consisting of CCR7, B3GAT1, VSIG4 and LRRN3 are determined.Type: GrantFiled: April 14, 2010Date of Patent: September 2, 2014Assignee: Cardiodx, Inc.Inventors: Steve Rosenberg, Whittemore G. Tingley, Michael R. Elashoff, James A. Winrove
-
Publication number: 20140156198Abstract: Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.Type: ApplicationFiled: January 16, 2014Publication date: June 5, 2014Applicant: CARDIODX, INC.Inventors: Steven Rosenberg, Michael R. Elashoff, Philip Beineke, James A. Wingrove, Whittemore G. Tingley, Susan E. Daniels
-
Publication number: 20130325356Abstract: Methods for ascertaining a dehydration or hydration level in a subject are described. The methods comprise determining the concentration of a salivary indicator and, in some embodiments, assigning a hydration or dehydration level based on the salivary indicator concentration after mathematical transformation of the value and with regard to previously-determined, transformed baseline values or with regard to a correlation.Type: ApplicationFiled: May 30, 2013Publication date: December 5, 2013Inventors: Michael R. Elashoff, James Patrick Reed
-
Publication number: 20130013219Abstract: Disclosed herein is a method of do terming the likelihood of a sudden cardiac event, such as an arrythmia, in a subject. Also disclosed is a method of determining whether a subject is at risk of a sudden cardiac event arid whether the subject would benefit from a treatment such as implantation of an ICD.Type: ApplicationFiled: March 18, 2011Publication date: January 10, 2013Applicant: CARDIODX ,INC.Inventors: Steven Rosenberg, Michael R. Elashoff, John Lincoln Blanchard, Susan Elizabeth Daniels, James Alan Wingrove, Amy Jo-Nell Sehnert
-
Publication number: 20120036101Abstract: Biomarkers useful for diagnosing and assessing physiological age are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers include a group of biomarkers whose expression levels are highly correlated to each other. In a preferred embodiment, expression levels of CD248; CD248 and SLC 1A7; CD248 and one, two, three or four of the group consisting of CCR7, B3GAT1, VSIG4 and LR-RN3; or CD248, SLC1A7 and one, two, three or four of the group consisting of CCR7, B3GAT1, VSIG4 and LRRN3 are determined.Type: ApplicationFiled: April 14, 2010Publication date: February 9, 2012Applicant: CARDIODX, INC.Inventors: Steve Rosenberg, Whittemore G. Tingley, Michael R. Elashoff, James A. Winrove
-
Publication number: 20110184712Abstract: Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene.Type: ApplicationFiled: October 10, 2008Publication date: July 28, 2011Applicant: CARDIODX, INC.Inventors: Steve Rosenberg, Susan Daniels, Michael R. Elashoff, James A. Wingrove, Whittemore G. Tingley, Amy J. Sehnert, Nicholas F. Paoni
-
Publication number: 20110015865Abstract: Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.Type: ApplicationFiled: June 15, 2010Publication date: January 20, 2011Applicant: CARDIODXInventors: Steven Rosenberg, Michael R. Elashoff, Philip Beineke, James A. Wingrove, Whittemore G. Tingley, Susan E. Daniels
-
Publication number: 20090197258Abstract: The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.Type: ApplicationFiled: March 6, 2008Publication date: August 6, 2009Inventors: Donna L. Mendrick, Mark W. Porter, Kory R. Johnson, Brandon Higgs, Arthur L. Castle, Michael Orr, Michael R. Elashoff
-
Patent number: 7469185Abstract: The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.Type: GrantFiled: February 4, 2003Date of Patent: December 23, 2008Assignee: Ocimum Biosolutions, Inc.Inventors: Donna L. Mendrick, Mark W. Porter, Kory R. Johnson, Brandon Higgs, Arthur L. Castle, Michael Orr, Michael R. Elashoff
-
Publication number: 20080215250Abstract: The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.Type: ApplicationFiled: April 30, 2007Publication date: September 4, 2008Inventors: Donna L. Mendrick, Mark W. Porter, Kory R. Johnson, Arthur L. Castle, Michael R. Elashoff
-
Publication number: 20040110193Abstract: Methods for classification of biological data including the use of mathematically based classification models are disclosed. In preferred embodiments, gene expression data derived from biological studies is used to classify events. The methods use a version of a linear discriminate model for deriving markers according to a technique whereby the model is limited to scoring the predictive ability of genes without making assumptions about inter-gene relationships, relative magnitudes or redundant information. In an associated method for building a fully informative database of biological information, biological studies are performed on a continual basis and linear discriminate models are used to provide rapid and efficient updates to gene markers.Type: ApplicationFiled: August 4, 2003Publication date: June 10, 2004Applicant: Gene Logic, Inc.Inventors: Arthur L. Castle, Michael R. Elashoff, Kory R. Johnson, Mark W. Porter
-
Publication number: 20020119462Abstract: The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.Type: ApplicationFiled: July 31, 2001Publication date: August 29, 2002Inventors: Donna L. Mendrick, Mark W. Porter, Kory R. Johnson, Arthur L. Castle, Michael R. Elashoff